- Home
- OMDA vs PCRX Comparison
OMDA vs PCRX Comparison
Compare OMDA & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMDA
- PCRX
- Stock Information
- Founded
- OMDA 2011
- PCRX 2006
- Country
- OMDA United States
- PCRX United States
- Employees
- OMDA N/A
- PCRX N/A
- Industry
- OMDA Medical/Nursing Services
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- OMDA Health Care
- PCRX Health Care
- Exchange
- OMDA Nasdaq
- PCRX Nasdaq
- Market Cap
- OMDA 1.3B
- PCRX 1.2B
- IPO Year
- OMDA 2025
- PCRX 2011
- Fundamental
- Price
- OMDA $19.00
- PCRX $24.47
- Analyst Decision
- OMDA Strong Buy
- PCRX Strong Buy
- Analyst Count
- OMDA 9
- PCRX 6
- Target Price
- OMDA $26.44
- PCRX $33.83
- AVG Volume (30 Days)
- OMDA 580.7K
- PCRX 715.1K
- Earning Date
- OMDA 11-06-2025
- PCRX 11-06-2025
- Dividend Yield
- OMDA N/A
- PCRX N/A
- EPS Growth
- OMDA N/A
- PCRX N/A
- EPS
- OMDA N/A
- PCRX 0.47
- Revenue
- OMDA $232,342,000.00
- PCRX $716,791,000.00
- Revenue This Year
- OMDA $43.42
- PCRX $7.27
- Revenue Next Year
- OMDA $20.01
- PCRX $10.18
- P/E Ratio
- OMDA N/A
- PCRX $51.75
- Revenue Growth
- OMDA 89.23
- PCRX 3.14
- 52 Week Low
- OMDA $14.14
- PCRX $16.00
- 52 Week High
- OMDA $28.40
- PCRX $27.64
- Technical
- Relative Strength Index (RSI)
- OMDA N/A
- PCRX 62.12
- Support Level
- OMDA N/A
- PCRX $23.25
- Resistance Level
- OMDA N/A
- PCRX $24.92
- Average True Range (ATR)
- OMDA 0.00
- PCRX 1.20
- MACD
- OMDA 0.00
- PCRX 0.38
- Stochastic Oscillator
- OMDA 0.00
- PCRX 92.17
About OMDA Omada Health Inc. Common Stock
Omada Health Inc empowers individuals to make lasting health changes through personalized, virtual care between doctor's visits. The integrated platform of the company supports members with cardiometabolic conditions like prediabetes, diabetes, hypertension, musculoskeletal issues, and behavioral health needs. The company's specialized care tracks also assist members using GLP-1 medications. The Company delivers measurable health outcomes and value for employers, health plans, health systems, and pharmacy benefit managers.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.